Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Investment analysts at Cantor Fitzgerald reduced their FY2023 EPS estimates for shares of Lucid Diagnostics in a research report issued to clients and investors on Wednesday, November 15th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($1.26) per share for the year, down from their prior forecast of ($1.14). Cantor Fitzgerald currently has a “Overweight” rating and a $4.00 target price on the stock. The consensus estimate for Lucid Diagnostics’ current full-year earnings is ($1.14) per share. Cantor Fitzgerald also issued estimates for Lucid Diagnostics’ FY2024 earnings at ($0.89) EPS.
Separately, Needham & Company LLC lowered their target price on shares of Lucid Diagnostics from $2.80 to $2.50 and set a “buy” rating for the company in a research note on Tuesday, November 14th.
Lucid Diagnostics Stock Down 0.8 %
Shares of Lucid Diagnostics stock opened at $1.30 on Monday. The firm’s 50 day moving average price is $1.32 and its 200-day moving average price is $1.43. Lucid Diagnostics has a 52-week low of $1.04 and a 52-week high of $2.12. The company has a market cap of $58.07 million, a P/E ratio of -1.00 and a beta of 1.81.
Institutional Trading of Lucid Diagnostics
Institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. acquired a new stake in Lucid Diagnostics in the 1st quarter worth approximately $209,000. Geode Capital Management LLC lifted its stake in Lucid Diagnostics by 245.3% during the 2nd quarter. Geode Capital Management LLC now owns 143,465 shares of the company’s stock valued at $199,000 after acquiring an additional 101,922 shares during the period. State Street Corp lifted its stake in Lucid Diagnostics by 24.4% during the 1st quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after acquiring an additional 11,121 shares during the period. Verition Fund Management LLC acquired a new stake in Lucid Diagnostics during the 1st quarter valued at approximately $122,000. Finally, Citadel Advisors LLC acquired a new stake in Lucid Diagnostics during the 2nd quarter valued at approximately $87,000. 4.30% of the stock is currently owned by institutional investors and hedge funds.
About Lucid Diagnostics
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.
- Five stocks we like better than Lucid Diagnostics
- How to Invest in Electric Cars
- The most upgraded stocks in November have two things in common
- 10 Best Airline Stocks to Buy
- Monday.com rocked earnings like it’s the weekend
- Your Comprehensive Guide to Investing in Bank Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.